As a main resource of food and various nutrients for the most living organisms including human and animals, plants are cultured and manufactured for long history. In addition to the contribution as food materials, plants are currently raised as novel resources to produce biopharmaceuticals in forms of enzyme, growth factor, peptide or antibody drugs with highly better productivity and wider diversity. While the traditional agriculture techniques, combined with techniques for developing transgenic plants, were used to supply these biopharmaceutical materials, some advanced plant scientists already tried and advanced to develop plant factory: an integrated system using indoor horticulture technology which can be managed with automatic regulation of environmental parameters, and controlled supplement of nutrition and energy resources. Plant factory system, with its enhanced productivity and strengthened antigenicity, could be utilized for manufacturing recombinant subunit vaccines, peptides as antigens and other various formulation such as virus like particles \[[@B1]\].

Since the functional monoclonal antibody was produced in tobacco \[[@B2]\], currently hundreds of recombinant proteins have been produced from various plants such as tobacco, rice, maize, potato, alfalfa, lettuce, tomato, carrot, and soybean \[[@B3]\]. Among those, bovine trypsin derived from maize has been commercialized since 2002 \[[@B4]\]. Glucocerebrosidase produced in carrot cell culture as the treatment of Gaucher\'s disease has been first approved for human use by United States Food and Drug Administration \[[@B3]\]. In addition, anti-Ebola antibody (known as ZMapp) produced in tobacco was used for human during 2014 West Africa Ebola virus outbreak \[[@B5]\]. Plant factory for vaccine production is basically same other nutrition or biopharmaceutical production, and also mainly use horticulture system within integrated shielding places such as greenhouses. Although plant-based human vaccines are not approved yet, several vaccine candidates against pathogens such as influenza, norovirus, hepatitis B virus, or rabies virus have been successfully produced in various transgenic plants and tested for their safety and efficacy under clinical trials ([Table 1](#T1){ref-type="table"}) \[[@B6][@B7][@B8][@B9][@B10][@B11][@B12]\]. For veterinary vaccine, Newcastle disease vaccine derived from tobacco cells was first approved for poultry use by United States Department of Agriculture \[[@B13]\]. In addition, many of recombinant viral proteins from plant system as human or veterinary vaccines have been tested for their immunogenicity against various viruses including human immunodeficiency virus, Ebola, rotavirus, Japanese encephalitis, foot-and-mouth disease virus, and bovine viral diarrhea virus \[[@B3][@B14]\].

Host plants for vaccine production can be grown massively in plant factory system than in conventional soil-based practice. Plant factory system uses artificial environment controlling CO~2~ concentration, light quality and quantity, temperature, humidity, and most importantly defined hydroponics media, which secures reproductive and cleaner conditions. Plant factory can supply more benefits to develop and produce vaccines as compared to conventional expression systems. For instance, in the case of pandemic outbreak of influenza, the fast production and scalability of plant factory could be attractive. While egg-based vaccine production takes at least 6 months, Medicago Inc. reported that the functional hemagglutinin (HA) virus like particle vaccine can be produced in plants within 21 days from identification of sequence for pandemic influenza \[[@B15]\]. The Fraunhofer Centre for Molecular Biotechnology also reported that it takes just over a month to yield purified HA antigens \[[@B16]\]. These vaccines have shown to be highly immunogenic in preclinical animal model, which showed protection against lethal virus challenge, and in human volunteers. Another advantage is probably lower expense for production and easier routines to get bulk stock proteins: 10 to 50 times lower than products derived from *Escherichia coli* and 140 times lower as compared to production of baculovirus-based insect cells \[[@B17]\]. In addition, plant expression system is safer than conventional expression platform because plants do not contain animal and human pathogens.

Despite of these advantages of plant expression system, only a few of vaccine candidates are under clinical trials and commercial human vaccines are not available due to low level of expression, relatively weak efficacy, and comparatively shallow knowledge on the characteristics of plant-made antigen and production system. It is a challenge to select target antigens carefully and proper plants for high production because the expression levels of the antigen depend on the particular target and specific host plant. An antigen may be highly compatible with one host plant, but not with others \[[@B18]\]. Lack of the consistency of transgene expression in different batches and individual plant within same batch is also a barrier for the application of the plant-based vaccine as an expected oral vaccine. Because of the antigen expression variability, evaluation of the vaccine doses required by individuals is quite challenging.

Glycosylation for the protein folding usually generates different surface affinity of the proteins. Plant specific glycosylation pathway consisting of N-glycan (core β-(1,2) xylose and core α-(1,3)) fucose moieties is another major challenge for substituting the plant-derived vaccine as an alternative bioreactors of mammalian cell culture due to allergic reactions \[[@B19]\]. However, this challenge has been overcome by either altering the pathway like targeting the antigen production in endoplasmic reticulum where high-Man-type N-glycans are produced or knocking out the α-(1,3) fucose and β-(1,2) xylose \[[@B20]\]. In other perspective, it could be seen as an advantage in that chances to alternate the folding formation of expressed proteins and binding capacity of the surface antigens. This property may generate more candidates for better vaccination efficacy or larger possibility to find working antigens for the diseases which are difficult for vaccine development such as acquired immune deficiency syndrome. It is notable that different plant polysaccharides are evaluated as adjuvants \[[@B21]\]. However, this issue should be addressed in the future.

Plant factory system was recognized as alternative resources for biopharmaceutical materials and vaccine candidates for a while. Now, techniques to exploit the advantages of plant factory for antigen production such as controlling glycosylation pattern is already established, and more valuable expansion using plants for vaccine development will be suggested and confirmed near future. Not only productivity or edibility, but also the characters to generate more diverse antigens which may not be produced by the microorganisms or mammalian cells should be real paws to consider the plant factory systems. The antigen production by plant factory could be a part of main vaccine development platform as well as alternative approaches. When plant factory is combined with gene-editing technologies, it can give us huge chances for many unmet and needed vaccine developments.
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###### Plant-derived human vaccines under clinical trails
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  Pathogen            Antigen                          Plant                     Clinical trial   Reference
  ------------------- -------------------------------- ------------------------- ---------------- ----------------
  Influenza H5N1      Hemagglutinin                    *Nicotiana benthamiana*   Phase I/II       \[[@B6][@B7]\]
  Influenza H1N1      Hemagglutinin                    *Nicotiana benthamiana*   Phase I          \[[@B8]\]
  Norovirus           Capsid protein                   Potato and tobacco        Phase I          \[[@B9]\]
  Hepatitis B virus   Surface protein                  Lettuce                   Phase I          \[[@B10]\]
  Hepatitis B virus   Surface protein                  Tobacco                   Phase I          \[[@B11]\]
  Rabies virus        Glycoprotein and nucleoprotein   Spinach                   Phase I          \[[@B12]\]
